Dec 3, 2019
|
Ardelyx Announces Positive Topline Results from Pivotal Phase 3 PHREEDOM Study Evaluating Tenapanor in CKD Patients on Dialysis
|
Dec 2, 2019
|
Ardelyx to Host Conference Call on December 3 to Review Results from the Pivotal Phase 3 PHREEDOM Study
|
Nov 26, 2019
|
Ardelyx to Present at the Piper Jaffray 31st Annual Healthcare Conference
|
Nov 25, 2019
|
Ardelyx and Kyowa Kirin Expand Partnership with Two Additional Agreements
|
Nov 6, 2019
|
Ardelyx Announces Presentation at Kidney Week 2019
|
Nov 6, 2019
|
Ardelyx Reports Third Quarter 2019 Financial Results and Recent Highlights
|
Oct 10, 2019
|
Ardelyx to Host Analyst Day in New York
|
Sep 17, 2019
|
Ardelyx to Present at the Ladenburg Thalmann 2019 Healthcare Conference
|
Sep 12, 2019
|
Ardelyx Receives FDA Approval for IBSRELA® (Tenapanor), an NHE3 Sodium Transport Inhibitor, for the Treatment of Irritable Bowel Syndrome with Constipation
|
Sep 3, 2019
|
Ardelyx Announces Positive Results from the Pivotal Phase 3 AMPLIFY Study Evaluating Tenapanor in Dialysis Patients Who Have Uncontrolled Hyperphosphatemia Despite Phosphate Binder Treatment
|